Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3585-3593

  Carrasco, Javier ^a,e   Van Pel, Aline ^a   Neyns, Bart ^b   Lethé, Bernard ^a   Brasseur, Francis ^a   Renkvist, Nicolina ^a   Van Der Bruggen, Pierre ^a   Van Baren, Nicolas ^a   Paulus, Robert ^d   Thielemans, Kris ^c   Boon, Thierry ^a   Godelaine, Danièle ^a,f  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^d Centre Hospitalier Peltzer La Tourelle   (Belgium)

^e Hopital St Joseph   (Belgium)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA A1 ANTIGEN; HLA DP ANTIGEN; MAGE 3.A1 PEPTIDE; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; UNCLASSIFIED DRUG; MAGEA3 PROTEIN, HUMAN; PEPTIDE FRAGMENT; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL CLONE; CELL MATURATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; MELANOMA; MIXED TUMOR; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SKIN METASTASIS; TREATMENT OUTCOME; ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN K 562; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY TEST; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; METASTASIS; METHODOLOGY; MOLECULAR GENETICS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 49149115482     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3585     Document Type: Article

References (40)

1. + melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7: 895s-901s.
2. Cebon, J., E. Jager, M. J. Shackleton, P. Gibbs, I. D. Davis, W. Hopkins, S. Gibbs, Q. Chen, J. Karbach, H. Jackson, et al. 2003. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 3: 7.
3. Slingluff, C. L., Jr., G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, et al. 2003. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21: 4016-4026.
4. Slingluff, C. L., Jr., G. R. Petroni, G. V. Yamshchikov, S. Hibbitts, W. W. Grosh, K. A. Chianese-Bullock, E. A. Bissonette, D. L. Barnd, D. H. Deacon, J. W. Patterson, et al. 2004. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22: 4474-4485.
5. Mitchell, M. S., W. Harel, R. A. Kempf, E. Hu, J. Kan-Mitchell, W. D. Boswell, G. Dean, and L. Stevenson. 1990. Active-specific immunotherapy for melanoma. J. Clin. Oncol. 8: 856-869.
6. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dréno, M.-H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80: 219-230.
7. Marchand, M., C. J. A. Punt, S. Aamdal, B. Escudier, W. H. J. Kruit, U. Keilholz, L. Håkansson, N. van Baren, Y. Humblet, P. Mulders, et al. 2003. Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: clinical report. Eur. J. Cancer 39: 70-77.
8. Kruit, W. H., H. H. van Ojik, V. G. Brichard, B. Escudier, T. Dorval, B. Dréno, P. Patel, N. van Baren, M.-F. Avril, S. Piperno, et al. 2005. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer 117: 596-604.
9. van Baren, N., M.-C. Bonnet, B. Dréno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Liénard, D. Speiser, M. Marchand, V. G. Brichard, et al. 2005. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23: 9008-9021.
10. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669-1678.
11. Godelaine, D., J. Carrasco, S. Lucas, V. Karanikas, B. Schuler-Thurner, P. G. Coulie, G. Schuler, T. Boon, and A. Van Pel. 2003. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J. Immunol. 171: 4893-4897.
12. Germeau, C., W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethe, E. De Plaen, T. Velu, et al. 2005. High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201: 241-248.
13. Lurquin, C., B. Lethé, V. Corbière, I. Théate, N. van Baren, P. G. Coulie, and T. Boon. 2005. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201: 249-257.
14. Tuyaerts, S., S. M. Noppe, J. Corthals, K. Breckpot, C. Heirman, C. De Greef, I. Van Riet, and K. Thielemans. 2002. Generation of large numbers of dendritic cells in a closed system using cell factories. J. Immunol. Methods 264: 135-151.
15. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921-930.
16. + cytolytic T lymphocytes. Cancer Res. 60: 6272-6275.
17. Brasseur, F. 1999. Melanoma: Brussels melanoma cell lines. In Human Cell Culture, Vol. 1. J. R. W. Masters and B. Palsson, eds. Kluwer Academic Publishers, Dordrecht, pp. 275-282.
18. De Plaen, E., K. Arden, C. Traversari, J. J. Gaforio, J.-P. Szikora, C. De Smet, F. Brasseur, P. van der Bruggen, B. Lethé, C. Lurquin, et al. 1994. Structure, chromosomal localization, and expression of twelve genes of the MAGE family. Immunogenetics 40: 360-369.
19. Lucas, S., E. De Plaen, and T. Boon. 2000. MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 87: 55-60.
20. Lethé, B., S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen, and T. Boon. 1998. LAGE-1, a new gene with tumor specificity. Int. J. Cancer 76: 903-908.
21. Guilloux, Y., S. Lucas, V. G. Brichard, A. Van Pel, C. Viret, E. De Plaen, F. Brasseur, B. Lethé, F. Jotereau, and T. Boon. 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183: 1173-1183.
22. Brichard, V. G., J. Herman, A. Van Pel, C. Wildmann, B. Gaugler, T. Wölfel, T. Boon, and B. Lethé. 1996. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol. 26: 224-230.
23. Brasseur, F., D. Rimoldi, D. Lienard, B. Lethé, S. Carrel, F. Arienti, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, et al. 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 63: 375-380.
24. Jäger, E., M. Ringhoffer, H. P. Dienes, M. Arand, J. Karbach, D. Jager, C. Ilsemann, M. Hagedorn, F. Oesch, and A. Knuth. 1996. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67: 54-62.
25. Zhang, Y., N. Renkvist, Z. Sun, B. Schuler-Thurner, N. Glaichenhaus, G. Schuler, T. Boon, P. van der Bruggen, and D. Colau. 2005. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4 peptide-pulsed dendritic cells. Eur. J. Immunol. 35: 1066-1075.
26. Godelaine, D., J. Carrasco, F. Brasseur, B. Neyns, K. Thielemans, T. Boon, and A. Van Pel. 2007. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol. Immunother. 56: 753-759.
27. Boon, T., J. Van Snick, A. Van Pel, C. Uyttenhove, and M. Marchand. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815: II. T lymphocyte-mediated cytolysis. J. Exp. Med. 152: 1184-1193.
28. Genevée, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22: 1261-1269.
29. Coulie, P. G., V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 98: 10290-10295.
30. Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, D. Colau, S. Lucas, A. Van Pel, K. Thielemans, N. van Baren, and T. Boon. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 101: 14631-14638.
31. Boon, T., P. G. Coulie, B. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
32. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, and S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182: 75-85.
33. Boon, T., and A. Van Pel. 1978. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. USA 75: 1519-1523.
34. Markiewicz, M. A., F. Fallarino, A. Ashikari, and T. F. Gajewski. 2001. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int. Immunol. 13: 625-632.
35. Lally, K. M., S. Mocellin, G. A. Ohnmacht, M. B. Nielsen, M. Bettinotti, M. C. Panelli, V. Monsurro, and F. M. Marincola. 2001. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 93: 841-847.
36. Butterfield, L. H., A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H.-J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, et al. 2003. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9: 998-1008.
37. Ribas, A., J. M. Timmerman, L. H. Butterfield, and J. S. Economou. 2003. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 24: 58-61.
38. Vignard, V., B. Lemercier, A. Lim, M. C. Pandolfino, Y. Guilloux, A. Khammari, C. Rabu, K. Echasserieau, F. Lang, M. L. Gougeon, et al. 2005. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol. 175: 4797-4805.
39. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl. J. Med. 319: 1676-1680.
40. Gajewski, T. F., Y. Meng, C. Blank, I. Brown, A. Kacha, J. Kline, and H. Harlin. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213: 131-145.